BACKGROUND: A disintegrin and metalloproteinase-12 (ADAM12) is a member of the greater ADAM family of enzymes: these are multifunctional, generally membrane-bound, zinc proteases for which there are forty genes known (21 of these appearing in humans). ADAM12 has been implicated in the pathogenesis of various cancers, liver fibrogenesis, hypertension, and asthma, and its elevation or decrease in human serum has been linked to these and other physiological/pathological conditions. SCOPE: In this review, we begin with a brief overview of the ADAM family of enzymes and protein structure. We then discuss the role of ADAM12 in the progression and/or diagnosis of various disease conditions, and we will conclude with an exploration of currently known natural and synthetic inhibitors. MAJOR CONCLUSION: ADAM12 has potential to emerge as a successful drug target, although targeting the metalloproteinase domain with any specificity will be difficult to achieve due to structural similarity between the members of the ADAM and MMP family of enzymes. Overall, more research is required to establish ADAM12 being as a highly desirable biomarker and drug target of different diseases, and their selective inhibitors as potential therapeutic agents. GENERAL SIGNIFICANCE: Given the appearance of elevated levels of ADAM12 in various diseases, particularly breast cancer, our understanding of this enzyme both as a biomarker and a potential drug target could help make significant inroads into both early diagnosis and treatment of disease.
BACKGROUND:A disintegrin and metalloproteinase-12 (ADAM12) is a member of the greater ADAM family of enzymes: these are multifunctional, generally membrane-bound, zinc proteases for which there are forty genes known (21 of these appearing in humans). ADAM12 has been implicated in the pathogenesis of various cancers, liver fibrogenesis, hypertension, and asthma, and its elevation or decrease in human serum has been linked to these and other physiological/pathological conditions. SCOPE: In this review, we begin with a brief overview of the ADAM family of enzymes and protein structure. We then discuss the role of ADAM12 in the progression and/or diagnosis of various disease conditions, and we will conclude with an exploration of currently known natural and synthetic inhibitors. MAJOR CONCLUSION:ADAM12 has potential to emerge as a successful drug target, although targeting the metalloproteinase domain with any specificity will be difficult to achieve due to structural similarity between the members of the ADAM and MMP family of enzymes. Overall, more research is required to establish ADAM12 being as a highly desirable biomarker and drug target of different diseases, and their selective inhibitors as potential therapeutic agents. GENERAL SIGNIFICANCE: Given the appearance of elevated levels of ADAM12 in various diseases, particularly breast cancer, our understanding of this enzyme both as a biomarker and a potential drug target could help make significant inroads into both early diagnosis and treatment of disease.
Authors: Nobuko Kawaguchi; Christina Sundberg; Marie Kveiborg; Behzad Moghadaszadeh; Meena Asmar; Nikolaj Dietrich; Charles K Thodeti; Finn C Nielsen; Peter Möller; Arthur M Mercurio; Reidar Albrechtsen; Ulla M Wewer Journal: J Cell Sci Date: 2003-08-12 Impact factor: 5.285
Authors: Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker Journal: Nat Rev Drug Discov Date: 2007-06 Impact factor: 84.694
Authors: Jennie Laigaard; Tina Sørensen; Sophie Placing; Peter Holck; Camilla Fröhlich; Karen R Wøjdemann; Karin Sundberg; Anne-Cathrine Shalmi; Ann Tabor; Bent Nørgaard-Pedersen; Bent Ottesen; Michael Christiansen; Ulla M Wewer Journal: Obstet Gynecol Date: 2005-07 Impact factor: 7.661
Authors: Xiang Wang; Fung Lan Chow; Tatsujiro Oka; Li Hao; Ana Lopez-Campistrous; Sandra Kelly; Stephan Cooper; Jeffrey Odenbach; Barry A Finegan; Richard Schulz; Zamaneh Kassiri; Gary D Lopaschuk; Carlos Fernandez-Patron Journal: Circulation Date: 2009-04-27 Impact factor: 29.690
Authors: Raffaele Serra; Luca Gallelli; Lucia Butrico; Gianluca Buffone; Francesco G Caliò; Giovanni De Caridi; Mafalda Massara; Andrea Barbetta; Bruno Amato; Miriam Labonia; Selena Mimmi; Enrico Iaccino; Stefano de Franciscis Journal: Int Wound J Date: 2016-03-15 Impact factor: 3.315